Search is Powered by Google
Cancer / Oncology News

State-of-the-Art Lecture: Aptomers Of Nanotechnology - Reported From The Annual Meeting Of The American Urological Association

Main Category: Cancer / Oncology
Article Date: 23 Jun 2008 - 0:00 PST

email icon email to a friend   printer icon printer friendly   write icon view / write opinions   rate icon rate article


Current Article Ratings:

Patient / Public:not yet rated

Health Professional:not yet rated

Article Opinions: 0 posts

ORLANDO, FL (UroToday.com) - Dr. Omid Farokhzad from Harvard addressed nanotechnology. Nanotechnology is the assembly of particles < 100nm. In 2004 the NCI formed the Alliance for Nanotech, which was followed by large government investments in this field. Nanotechnology can be used across the spectrum of medicine to include prevention, diagnostics and therapeutics. Nano-drugs are in the form of liposomes, polymeric platforms and other platforms. Polymer nanoparticles or liposome-polymers have a core that encapsulates a drug to protect it from the immune system. On the surface are ligands to recognize the target tissue. For example, perhaps siRNA could be delivered to tissues using nanoparticles. Nanoparticles leave the vascular space to deliver drugs to the target. The drug can then be released in cells at higher concentrations than via system means.

The complexity of designing, developing and manufacturing of nanoparticles is immense. There are 18 naked ligands that are presently approved, but no nanoparticle conjugates are presently approved. He showed examples of targeting approaches with aptamers. A PSMA aptamer was developed as a bioconjugate that could mark specific cells. They went on to alter the amount of ligand on the surface and found that increased targeting ligand results in greater recognition by the immune system. Thus ligand density is critical to nanoparticle formulation. Aptamers can be delivered to prostate cancer cells and they become internalized in 30 minutes time. He showed an example of combining therapeutic and imaging particles in one complex with quantum dot expression providing measurable information on drug delivery. He reports that a first test of therapy will be in HRPC patients in 2009.

Presented by Omid Farokhzad, MD, at the Annual Meeting of the American Urological Association (AUA) - May 17 - 22, 2008. Orange County Convention Center - Orlando, Florida, USA.

Reported by UroToday.com Contributing Editor Christopher P. Evans, MD, FACS

UroToday - the only urology website with original content written by global urology key opinion leaders actively engaged in clinical practice.

To access the latest urology news releases from UroToday, go to: www.urotoday.com

Copyright © 2008 - UroToday




Personalized Homepage Weekly Newsletters Daily News Alerts
Opioid Induced Constipation ADHD Anxiety Asthma Autism Cancer Diabetes Lung Cancer Lupus Medicare / Medicaid Obesity and BMI Pancreatic Cancer Stem Cells All 'What Is...' Articles All 'How To...' Articles

Ophthalmology Urology
About Us News Licensing Free Website Feeds Free Tools & Content Tell a Friend Accessibility Help / FAQ Article Submission Links Contact Us

add medical news today to your facebook
medical news gadget

Swine Flu Image

Swine Flu Updates

- Latest Swine Flu News
- What is Swine Flu?
- Map Of H1N1 Outbreaks
- Swine Flu - Top 20 FAQ
- Daily Email News Alerts
Stick with Medical News Today for the latest news updates on swine flu.


These are the most read articles from this news category for the last 6 months:
Top Article Star
Understanding And Treating Triple-Negative Breast Cancer
07 Jan 2009
Triple-negative breast cancer is a subtype of breast cancer that is clinically negative for expression of estrogen and progesterone receptors (ER/PR) and HER2 protein. It is characterized by its unique molecular profile...


Monitoring and Adherence in CML image Monitoring and Adherence in CML

Imatinib, or Gleevec, is a targeted anti-cancer drug that can keep chronic myelogenous leukemia (CML) in check for most patients for many years. It is important for patients to take imatinib as prescribed by their doctor to fight the disease and to guard against resistance...

Treating HER2+ Breast Cancer image Treating HER2+ Breast Cancer

There are at least four different kinds of breast cancer and each is treated differently. For HER2+ breast cancer, a chemotherapy drug is typically the best option. Here's an overview of the drugs used to treat breast cancer...

View more videos...